Angelina Jolie's long-rumored relocation plans are very much alive and gaining momentum, according to close sources.

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.

Angelina Jolie has shockingly faced a torrent of callous online abuse after boldly baring the scars from her double ...

Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

London man Dan Godley survived stage three pancreatic cancer with support from his fiancée, a dachshund puppy and groundbreaking treatment. He ...

A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center ...

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to ...

The Phase 3 AMPLITUDE trial led by UCL found that adding the PARP inhibitor niraparib to standard hormone therapy may slow ...

In this retrospective study, researchers aimed to characterize persistent toxicities experienced by patients with TNBC who were treated with pembrolizumab in the curative setting.

Use of MHT following menopause is not associated with an increased risk for breast cancer among BRCA1 and BRCA2 carriers.